Cancer genomics — from bench to bedside

The advent of massively parallel sequencing technologies has driven the analysis of cancer genomes

at an unprecedented resolution. Sequence data from thousands of patients highlight the distinct sets

of driver mutations among patients with the same cancer tissue type, and single-cell sequencing

technologies have revealed heterogeneity within the subclones of single tumours as they evolve. Identifying and characterizing these mutations and their diversity is essential for the development of personalized therapies. Next-generation sequencing technologies have also been applied to study the epigenomes

and transcriptomes of cancer, thus paving the way for an integrated understanding of cancer pathology.

This collection, which includes articles from Nature Reviews Genetics, Nature Reviews Clinical Oncology andNature Reviews Cancer, showcases how cancer genomics has informed our understanding of cancer pathogenesis, unravelled potential future therapeutic targets and driven advances that are starting to translate into the clinic. This resource provides a comprehensive bench-to-bedside overview of cancer genomics, which will be useful to researchers and clinicians alike.